Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Non Operating Income: 2021-2025

Historic Non Operating Income for Agios Pharmaceuticals (AGIO) over the last 4 years, with Sep 2025 value amounting to $67,000.

  • Agios Pharmaceuticals' Non Operating Income fell 95.94% to $67,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 47.30%. This contributed to the annual value of $6.5 million for FY2024, which is 7.13% up from last year.
  • Agios Pharmaceuticals' Non Operating Income amounted to $67,000 in Q3 2025, which was down 87.19% from $523,000 recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Non Operating Income ranged from a high of $4.6 million in Q3 2021 and a low of $67,000 during Q3 2025.
  • Its 3-year average for Non Operating Income is $1.3 million, with a median of $1.6 million in 2024.
  • In the last 5 years, Agios Pharmaceuticals' Non Operating Income soared by 37.81% in 2024 and then plummeted by 95.94% in 2025.
  • Agios Pharmaceuticals' Non Operating Income (Quarterly) stood at $3.3 million in 2021, then tumbled by 58.48% to $1.4 million in 2022, then increased by 26.23% to $1.7 million in 2023, then declined by 5.25% to $1.6 million in 2024, then slumped by 95.94% to $67,000 in 2025.
  • Its Non Operating Income was $67,000 in Q3 2025, compared to $523,000 in Q2 2025 and $1.3 million in Q1 2025.